Grass pollen allergy is the common health problem that affects approximately 400 million people worldwide. The world’s first vaccine developed against grass pollen allergy have shown positive results in the phase 2 trials and reported that 4 injections of the vaccine BM32 in the 1 st year and a top-up in the 2 nd year of treatment may relieve the patient’s symptoms by at least 25%. The newly developed vaccine - BM32 - is based on recombinant fusion proteins consisting of nonallergenic peptides from the IgE-binding sites of the 4 major grass pollen allergens and the hepatitis B preS protein.
Clinical evidence A double-blind, placebo-controlled clinical study investigated the safety and clinical efficacy of allergen immunotherapy with BM32 in patients with grass pollen-induced rhinitis and controlled asthma. A total of 181 subjects were randomized to receive 3 pre-seasonal injections of…
